Bone Targeting Agents in Patients with Prostate Cancer – APCCC

APCCC shared a post on LinkedIn:

“Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.

Bone metastases are a common and critical complication of advanced Prostate Cancer , affecting around 90% of patients.

Effective management of bone involvement, particularly through the use of bone-targeting agents (BTAs) such as bisphosphonates and denosumab, is crucial for reducing skeletal-related events (SREs) and improving survival in metastatic cases.

However, these treatments carry risks, particularly osteonecrosis of the jaw (ONJ), a serious and debilitating side effect.

This review discusses the clinical benefits, common toxicities, and management strategies associated with BTAs in prostate cancer, with a focus on understanding and addressing ONJ.”

Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw

Authors: Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, and Francesco Massari.

Source: APCCC/LinkedIn